Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 32Pain, Postoperative 18Neoplasms 15Parkinson Disease 4, Autosomal Dominant Lewy Body 13Lung Neoplasms 12Brain Neoplasms 12Prostatic Neoplasms 9Ovarian Neoplasms 8Colonic Neoplasms 8Carcinoma, Hepatocellular 8Stomach Neoplasms 7Depression 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Pain 6Head and Neck Neoplasms 6Thyroid Neoplasms 5Pancreatic Neoplasms 5Multiple Myeloma 5Leiomyoma 5Agnosia 5Neoplasm Metastasis 4Lymphoma 4Fatigue 4Delirium 4Anxiety Disorders 4Urinary Bladder Neoplasms 3Thromboembolism 3Supratentorial Neoplasms 3Stomatitis 3

Interventions

Metformin 3fluorodopa F 18 2Clomiphene 2pasireotide 1dapagliflozin 1amino-acid, glucose, and electrolyte solution 1Surveys and Questionnaires 1Sugars 1Solutions 1Saline Solution 1Pioglitazone 1Insulin 1Injections 1Diazoxide 1Amino Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hyperinsulinism × Saline Solution × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡